POMC and pituitary tumor: Pasireotide, a multireceptor-targeting somatostatin analogue (SSA), which targets the ACTH-secreting pituitary tumor, is the first medical therapy approved for the treatment of adult CD patients for whom surgery has failed or is not an option [1, 7].